To evaluate the relation between the presence of cancer cells in blood according to the time course during a surgical procedure and liver metastases in patients with gastric cancer.
Objective
To evaluate the relation between the presence of cancer cells in blood according to the time course during a surgical procedure and liver metastases in patients with gastric cancer.
Summary Background Data
Several studies have reported on the detection of circulating cancer cells in blood by reverse transcriptase-polymerase chain reaction (RT-PCR). However, few reports have examined the relation between molecular detection of circulating cancer cells according to the time course during a surgical procedure and blood-borne metastases.
Methods
Blood samples from 57 patients with gastric cancer were obtained from the portal vein, peripheral artery, and superior vena cava before and after tumor dissection. After total RNA was extracted from each blood sample, carcinoembryonic antigen (CEA)-specific RT-PCR was performed.
Results
CEA-mRNA was detected in the blood of 21 (36.8%) of the 57 patients. CEA-mRNA was not detected in the blood obtained from 15 healthy volunteers and 15 patients with benign disease. The positive rate increased in proportion to the depth of tumor. The incidence of positive CEA-mRNA did not differ among the various sites of blood sampling. The appearance of circulating cancer cells was related to the surgical maneuver. A significant relation was found between the detection of CEA-mRNA and blood-borne metastases.
Conclusions
A high incidence of positive CEA-mRNA was found in the blood during gastric cancer surgery. Surgical maneuvers are a possible cause of hematogenous metastasis. The authors found that patients with positive CEA-mRNA had a high risk of blood-borne metastasis even after curative resection.
Blood-borne metastasis, including liver metastasis, is one of several important prognostic factors in patients with gastric cancer undergoing curative resection. 1, 2 Even in patients with early gastric cancer, blood-borne metastasis occurs. [3] [4] [5] In animal studies, cancer cells have been observed to shed into the bloodstream during surgical manipulation of a primary tumor. 6, 7 In turn, this shedding of cancer cells into the bloodstream enhanced the distant metastasis. 8, 9 Circulating cancer cells are now easily detectable with polymerase chain reaction (PCR) or reverse transcriptasepolymerase chain reaction (RT-PCR). There have been several studies on the detection of circulating cancer cells in the blood by PCR or RT-PCR. 10 -15 Eschwege et al 16 showed the dissemination of prostatic epithelial cells during radical prostatectomy in patients with prostatic cancer by RT-PCR. Brown et al 17 detected tumor cell dissemination during surgery in patients with breast cancer using RT-PCR. However, relatively few reports have examined the presence of cancer cells in blood samples from various sites or investigated the relation between the detection of circulation of cancer cells and blood-borne metastases. Gerhard et al 18 established carcinoembryonic antigen (CEA)-specific RT-PCR in 1994. Mori et al 19 detected circulating cancer cells in patients with gastric cancer by CEA-specific RT-PCR. Funaki et al 20 detected CEA-mRNA in the circulating peripheral blood in patients with gastric cancer using their own CEA-specific RT-PCR method. Thus, the CEA-specific RT-PCR method is useful for detecting circulating cancer cells in patients with gastric cancer.
We performed CEA-specific RT-PCR on blood samples from several vessels to investigate the relation between the detection of circulating cancer cells during surgery and blood-borne metastases. Thus, the present study examines circulating cancer cells from various sites according to the time course during a surgical procedure and attempts to determine the relation between the appearance of cancer cells in blood as a result of surgical maneuvers and liver metastasis in patients with gastric cancer.
METHODS

Study Group
This study included 57 consecutive patients with gastric cancer who underwent a curative resection at the First Department of Surgery, Kagoshima University, from 1996 to 1997. None of them had received preoperative radiation therapy or chemotherapy. Of the 57 patients, total gastrectomy was performed in 21, distal gastrectomy in 25, proximal gastrectomy in 9, and partial gastrectomy in 2. Clinicopathologic features are shown in Table 1 . Clinical stage was assigned according to Japanese Classification of Gastric Carcinoma, second English edition. 21
Blood Samples
Blood samples were obtained from the 57 patients with gastric cancer, 15 patients with benign disease, and 15 healthy volunteers after obtaining consent. All subjects, excluding the healthy volunteers, underwent laparotomy. To prevent contamination of epithelial cells, 5-mL samples of heparinized blood were obtained from each of three catheters inserted into the portal vein, peripheral artery, and superior vena cava. Blood samples from the portal vein were obtained from a catheter inserted into the umbilical vein after the laparotomy. Blood samples from the peripheral artery were obtained from a catheter used to monitor arterial blood pressure during general anesthesia. Blood samples from the superior vena cava were obtained from a catheter used to monitor central venous pressure during general anesthesia. Blood samples were obtained twice, before and during surgery. For the purpose of this study, the term "before resection" was defined as just after the laparotomy, and the term "after resection" was defined as just before the tumor resection. Peripheral venous blood was used as the blood sample for healthy volunteers after discarding the initial 20 mL blood to protect the mixture of epithelial cells. In this report, we refer to the blood samples obtained during the tumor resection as intraoperative blood samples.
Cell Lines
To prepare for CEA-specific RT-PCR, we used two cell lines, MCF-7 (breast cancer cell line) and KATO-III (gastric cancer cell line). Lymphocytes were collected from healthy volunteers who showed no signs of epithelial malignancy. After isolating lymphocytes from the peripheral blood by gradient centrifugation, the mononuclear cell layer was collected. Cell lines were sequentially diluted to 10-fold dilution in 2 to 5 ϫ 10 7 lymphocytes to yield ratios ranging from 1:10 to 1:10 5 (carcinoma cells to lymphocytes).
RNA Extraction
The fraction of nucleated cells was obtained using Monopoly resolving medium (Dainippon Pharmaceutical Co. Ltd., Osaka, Japan). Blood samples were diluted by the addition of 2 mL 0.05 mol/L phosphate-buffered saline. Diluted samples were layered on 4 mL Mono-poly resolving medium. Each sample was centrifuged at 400g at room temperature for 20 minutes. The cell layer was then collected into 40 mL phosphate-buffered saline. The fraction of nucleated cells was collected after being centrifuged at 250g at 4°C for 15 minutes. The resulting fraction of nucleated cells was suspended in 1 mL Isogen (Nippon Gene, Toyama, Japan) and stored at Ϫ80°C until use.
Total RNA was extracted using Isogen. The RNA extraction method used conformed to the manufacturer's protocol. Total RNA was dissolved in 10 L diethylpyrocaronatetreated water. The volume and quality of total RNA obtained were assessed by an absorption measurement at 260 and 280 nm using the UV-visible spectrophotometer Bio-Spec-1600 (Shimazu Co., Kyoto, Japan). Before the synthesis of cDNA, deoxyribonuclease I (DNase I) (Stratagene, La Jolla, CA) was added to each sample of total RNA. One-half unit DNase I and 1 L 10ϫ buffer (Takara Shuzo Co., Ltd., Otsu, Japan) were added to 5 g total RNA in a total volume of 9.5 L. The reaction mixture was incubated for 60 minutes at 37°C. Next, 1.5 L of 20 mmol/L ethylenediaminetetraacetic acid (EDTA) was added. An 11-L aliquot of reaction mixture was incubated for 20 minutes at 70°C and quickly chilled on ice. After 50 ng random hexamer was added, 5 g total RNA in a volume of 12 L was incubated for 10 minutes at 72°C and quickly chilled on ice. One microliter 10ϫ buffer, 2 L of 25 mmol/L MgCl 2 , 1 L of 0.1 mol/L dithiothreitol (DTT), 1 L of 10 mmol/L deoxyribonucleoside triphosphate (dNTP) mix, and 2 L diethylpyrocaronate water were added to the reaction mixture. A 19-L aliquot of reaction mixture was incubated for 10 minutes at 25°C. Next, 100 units Super Script II RT (Life Technologies, Inc., Rockville, MD) was added to the reaction mixture, which was then incubated for 15 minutes at 25°C, 90 minutes at 42°C, 15 minutes at 70°C, and then quickly chilled on ice. One unit Escherichia coli RNase H (All Life Technologies, Inc., Rockville, MD) was added to the reaction mixture. A 20-L aliquot of reaction mixture was incubated for 40 minutes at 37°C. Next, 5 L tris-EDTA was added to cDNA, which was then stored at Ϫ20°C until use.
To monitor the synthesis of cDNA, glyceraldehyde-3phosphatase dehydrogenase (GAPDH) RT-PCR was performed using a published GAPDH primer. 22 The GAPDH up-primer was 5Ј-TCCCATCACCATCTTCCCA-3Ј and the GAPDH down-primer was 5Ј-CATCACGCCACAGTT-TCC-3Ј. Next, 0.5 L cDNA, 5 L 10ϫ PCR buffer, 200 mol/L dNTP mixture, 0.2 mol/L up-primer, 0.2 mol/L down-primer, and 1.25 unit Taq DNA polymerase (all Takara Shuzo) were added to a 40-L sample of PCR mixture. Denaturation for 4 minutes at 95°C was carried out.
Amplification was performed with denaturation for 4 minutes at 95°C, annealing for 1 minute at 57°C, extension for 50 seconds at 72°C for 40 cycles, followed by a final extension for 9 minutes at 72°C. The GAPDH RT-PCR product was separated using the 2% agarose gel electrophoresis in Tris-acetate-EDTA buffer and visualized by ethidium-bromide staining. The RT-PCR product was detected as a 390-base pair fragment.
RT-PCR
To detect CEA mRNA more accurately, we performed nested RT-PCR. We used three different CEA primers designed by Gerhard et al. 18 The CEA-A primer was 5Ј-TCTG-GAACTTCTCCTGGTCTCTCAGCTGG-3Ј, the CEA-B primer was 5Ј-TGTAGCTGTTGCAAATGCTTTAAGGAAGAAGC-3Ј, and the CEA-C primer was 5Ј-GGGCCACTGTCGGCAT-CATGATTGG-3Ј. In first RT-PCR, 0.5 L cDNA, 2 L 10ϫ PCR buffer, 200 mol/L dNTP mixture, 0.2 mol/L CEA primer A and primer B, and 0.5 unit Taq DNA polymerase (all Takara Shuzo) were added to a 20-L aliquot of reaction mixture. Denaturation for 4 minutes at 95°C was carried out. Amplification was performed with denaturation for 30 seconds at 95°C, annealing for 1 minute at 69°C, extension for 30 seconds at 72°C for 30 cycles, followed by a final extension for 6 minutes at 72°C. In nested RT-PCR, 1 L of first PCR product, 4 L of 10ϫ PCR buffer, 200 mol/L dNTP mixture, 0.2 mol/L CEA primer B and primer C, and 1 unit Taq DNA polymerase (all Takara Shuzo) were added to a 40-L aliquot of reaction mixture. Denaturation for 4 minutes at 95°C was carried out. Amplification was performed with denaturation for 30 seconds at 95°C, annealing for 1 minute at 64°C, extension for 30 seconds at 72°C for 32 cycles, followed by a final extension for 6 minutes at 72°C. The CEA RT-PCR product was separated using 2% agarose gel electrophoresis in Tris-acetate-EDTA buffer and visualized by ethidium-bromide staining, and the RT-PCR product was detected as a 131-base pair fragment.
CEA-specific nested RT-PCR was performed twice per sample. Samples were judged as positive for CEA-mRNA only when a 131-base pair fragment was detected in both assays. Three kinds of samples (water, the stock sample obtained from the healthy volunteers, and the stock sample obtained from MCF-7 cell line) were always used as a quality control in each assay.
Clinical Follow-Up
All patients were followed up after discharge by physical examination, routine blood tests, serum tumor marker tests, and x-ray examination every 1 to 3 months, computed tomography every 3 to 6 months, and ultrasonography every 6 months. Follow-up data after surgery were obtained for all patients, with a median follow-up period of 15 months (range 6 -30 months).
Statistical Evaluation
All data were statistically compared using a chi-square test and a Student t test, with P Ͻ .05 considered significant.
RESULTS
CEA-mRNA was detected in MCF-7 and KATO-III cell lines. CEA-mRNA was detectable at a concentration as low as one tumor cell per 10 6 normal lymphocytes. No signals of CEA-mRNA were detected in the blood from patients with benign disease or in lymphocytes from healthy volunteers.
Of the 57 patients with gastric cancer, 21 (36.8%) were positive for CEA-mRNA (Fig. 1) . The positive rates for each clinical were as follows: stage I, 17.5% (7/40); stage II, 83.3% (5/6); stage III, 100% (7/7); and stage IV, 60% (3/5). The positive rates according to depth of tumor invasion were 17.1% (6/35) in T1, 58.3% (7/12) in T2, 75.0% (6/8) in T3, and 100% (2/2) in T4. CEA-mRNA was not detected in any of the 18 patients with lesions confined to the Vol. 233 • No. 2 mucosa. The positive rates for CEA-mRNA did not increase as the clinical stage advanced. However, the positive rate was seen to increase with the tumor depth (P Ͻ .001) (Fig. 2) .
The positive rate of CEA-mRNA according to the site of the blood sample was 18.4% (9/49) in the portal vein, 17.5% (10/57) in the peripheral artery, and 21.6% (11/51) in the superior vena cava. CEA-mRNA positivity did not differ among the blood sample sites. When comparing the detection of CEA-mRNA before and after dissection, 36 patients showed no positive CEA-mRNA signals either before or after resection and 2 patients showed positive signals in both ( Table 2 ). The positive rate for CEA-mRNA was 8.8% (5/57) before dissection and 33.3% (19/57) after dissection. Tumor depth and clinical stage of the five patients with positive preoperative findings were T1/Ia, T1/Ib, T2/Ib, T3/IVb, and T4/IVb. In 16 patients, CEA-mRNA was negative before dissection but positive after dissection. The positive rate for CEA-mRNA after dissection was greater than that before dissection (P ϭ .02).
Recurrence after surgery was found in eight patients despite curative resection. Six of 21 patients with positive CEA-mRNA expression and 2 of 36 patients with negative CEA-mRNA expression had recurrent disease. The incidence of recurrence was significantly greater in patients with CEA-mRNA positivity than in those with negativity (P Ͻ .05). The relation between the mode of recurrence and CEA-mRNA expression is shown in Table 3 .
Liver metastasis occurred in four patients. Tumor depth and stage for these patients were T2/II, T2/IIIa, T3/IIIb, and T3/IVb. Positive findings of CEA-mRNA were detected in all four patients. One patient was positive for CEA-mRNA only before dissection, whereas three patients were positive for CEA-mRNA only after dissection (Table 4 ). In contrast, blood-borne metastasis was not detected in any of the 36 patients who showed no CEA-mRNA signal. A significant relation was found between the expression of CEA-mRNA and liver metastases (P ϭ .03) ( Table 5 ).
DISCUSSION
Blood-borne metastasis occurs in three steps: attachment, proteolysis, and cell motility. 23 Detection of free cancer cells in the blood may be a clue for elucidating cell motility. In the present study, we simultaneously examined blood samples from three different vessels (the portal vein, peripheral artery, and superior vena cava) to increase the possibility of detecting circulating cancer cells. We also analyzed the relation between the detection of cancer cells and surgical manipulation.
We used a CEA-mRNA primer for detecting circulating cells because CEA-mRNA is present in all epithelial cells, including cancer cells. 18 During collection of blood samples, contamination by normal epithelial cells proved problematic. To prevent contamination of epithelial cells, all blood samples were obtained after inserting the catheter into each of three vessels. Blood samples from the healthy volunteers were obtained from the peripheral vein after discarding the initial 20 mL blood to prevent contamination by dermal epithelial cells. No CEA-mRNA signals were detected in either the patients with benign disease or the healthy volunteers. In a previous study, we examined CEA-mRNA expression of peripheral blood in 15 patients with unresectable tumors (biliary-pancreatic cancer, 3; gastric cancer, 2; liver metastasis, 10). The signal of CEA-mRNA was detected in all patients. Similarly, CEA-mRNA primer has been used as a marker to identify circulating cancer cells in the blood. 13, [17] [18] [19] [20] Therefore, we concluded that circulating cancer cells had been effectively identified by our CEAspecific RT-PCR method.
Although the positive rate for CEA-mRNA did not increase as the clinical stage advanced, it increased in proportion to the depth of tumor invasion. The staging system was generally defined not only by the tumor depth but also by lymph node metastasis and distant metastasis. The appearance of circulating cancer cells in the blood may correspond to primary tumor development, given that tumors with deep invasion showed a strong tendency to infiltrate into blood capillaries in the gastric wall.
We obtained blood samples not only from the peripheral artery, but also from the superior vena cava and portal vein. In general, cancer cells flow primarily into the liver from the primary lesion through the portal vein. Fisher and Turnbull 24 showed the existence of cancer cells in drainage veins and detected tumor cells in the blood of the major mesenteric venous channels in 8 of 25 patients with colorectal cancer using a perfusion technique. Although we predicted a high positivity rate for CEA-mRNA in the portal vein compared with blood samples in the peripheral artery and the superior vena cava, the observed rate did not differ significantly among the various sites.
The total number of patients with positive CEA-mRNA was 19, and 16 of these patients had positive CEA-mRNA findings only after dissection, which suggests that cancer cells may detach easily from primary tumors and flow into blood vessels as a result of surgical maneuvers. Nishizaki et al 9 reported an association between detachment of cancer cells resulting from surgical manipulation and blood-borne metastases in animal studies. Mori et al 25 examined the detection of circulating cancer cells by RT-PCR in 62 patients who had undergone curative resection of gastrointestinal or breast carcinomas. They concluded that because metastatic disease later developed in 4 of 12 positive patients, the detection of circulating cancer cells in the peripheral blood may be a powerful marker for the prediction of tumor relapse after surgery. In the present study, liver metastases occurred in four patients who underwent cura- tive resection despite the short follow-up. A significant relation was found between the detection of CEA-mRNA and liver metastases. Examination of CEA-mRNA in the blood was thought to be a useful means of predicting blood-borne metastasis.
In conclusion, we demonstrated a high frequency of cancer cell detection by RT-PCR using CEA-mRNA in patients with gastric cancer. Surgical maneuvers play an important role in the process involved in the detachment of primary tumor cells to the systemic circulation. Patients with positive CEA-mRNA have a high risk of blood-borne metastasis even after curative resection. Therefore, some treatments, including blocking the blood flow of the gastric wall that includes the primary tumor, clamping large vessels such as the left and right gastric artery, and administering adjuvant chemotherapy, should be done to prevent blood-borne metastases.
